Skip to main content
. 2022 Apr 16;12(12):4446–4457. doi: 10.1016/j.apsb.2022.04.007

Figure 4.

Figure 4

P39 attenuates PD-1/PD-L1 interaction and strengthens the cytotoxicity of PBMCs. (A) Binding of PD-1 to H460 cells, which were treated with the indicated dose of P39 for 24 h, was measured by flow cytometry. The Y-axis shows the mean fluorescence intensity of PD-1. (B) After treatment with P39 (0–200 nmol/L, 24 h) on the MDA-MB-231 and H460 cells, the changes in immunostaining were monitored. The green fluorescence intensity indicates the binding of PD-1 to tumor cells. (C) Addition anti-PD-L1 inhibitor that interfered with the PD-1/PD-L1 interaction results in NFAT-RE-mediated luminescence. (D) Interaction of PD-1/PD-L1 between Jurkat NFAT-luciferase reporter cells and P39-treated A549 or H358 cells were measured using the PD-1/PD-L1 blockade assay. Data are shown as fold induction compared to untreated controls.